BioSpace News Archive

With flu season fast approaching, Genentech has some good news for people who are at high risk of complications from the illness.

HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.”

Fresh off its first Pipeline Day last week, Vivek Ramaswamy’s Roivant Sciences is taking aim at breaking into the Chinese market. Roivant has launched another company called Sinovant Sciences.

Absence epilepsy is the most common type of seizure disorder in children and is the focus of a new neurology study at Baylor College of Medicine and published in the journal Nature Communications.

The good news keeps coming for Janssen Pharmaceuticals’ SGLT2 diabetes drug Invokana. Late Monday the company said it was halting its Phase III chronic kidney disease trial early due to the fact that the drug had already achieved pre-specified efficacy data.

With the June approval of Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s Neulasta (pegfilgrastim), the company is facing a potential revenue problem as the Mylan drug is expected to cut into Amgen’s market share.

Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer.

AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.

One month after sharing promising interim-Phase I data at the American Society of Clinical Oncology, China-based Ascentage Pharma secured $150 million in Series C financing that will be used to support the development of its pipeline.

Toni Foster appointed to the position of Senior VP of Medical Operations and Program Management [17-July-2018] SAN DIEGO, July 17, 2018 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the appointment of Craig Thompson as President and CEO. Craig brings ove